Back to Agenda
Session 1 continued: Adverse Reaction Reporting and Analysis, EudraVigilance System Changes to Come
Speaker(s)
Signal Management at the EMA, Planned Revision of GVP Module IX (Signal Management) and the Scientific Guideline on Signal Detection
Georgy Genov, MD
European Medicines Agency, Netherlands
Head of Pharmacovigilance Office
Industry Readiness for the New EudraVigilance
David John Lewis, PhD
Novartis Pharma Gmbh, Switzerland
Former Head QPPV PRRC Office, Patient Safety & Pharmacovigilance
Have an account?